Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;43(4):378-82.
doi: 10.1016/j.ijantimicag.2014.01.016. Epub 2014 Feb 14.

Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia

Thana Khawcharoenporn  1 , Nattapol Pruetpongpun  2 , Pimsiri Tiamsak  3 , Sasinuch Rutchanawech  2 , Linda M Mundy  4 , Anucha Apisarnthanarak  2
Affiliations

Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia

Thana Khawcharoenporn et al. Int J Antimicrob Agents. 2014 Apr.

Abstract

Data for treatment and outcomes of extensively drug-resistant Acinetobacter baumannii (XDR-AB) pneumonia are limited. A retrospective cohort study of 236 adult patients with XDR-AB pneumonia was conducted between January 2009 and December 2012. The median age of subjects was 70 years (range 17-95 years), 53% were male, 55% had ventilator-associated pneumonia and 42% had been admitted to the intensive care unit. All XDR-AB isolates were susceptible only to tigecycline and colistin; 52 (22%) of the 236 subjects did not receive an agent active against XDR-AB, with an associated 28-day survival of 0%. Colistin-based two-drug combination treatment was prescribed to 166 subjects (70%); regimens included (i) colistin and high-dose sulbactam (n=93); (ii) colistin and tigecycline (n=43); and (iii) colistin and high-dose prolonged infusion of a carbapenem (n=30). The 28-day survival rate and mean length of hospital stay were not statistically different between these three regimens (65%, 53% and 60% and 39, 39 and 38 days, respectively). Predictors of mortality included Acute Physiology and Chronic Health Evaluation (APACHE) II score [adjusted odds ratio (aOR)=1.11; P<0.001 for each point increase], duration from infection onset to receipt of active regimen (aOR=1.01; P=0.002 for each hour delay), underlying malignancy (aOR=3.46; P=0.01) and chronic kidney disease (aOR=2.85; P=0.03). These findings suggest that the three colistin-based two-drug combination regimens may be treatment options for XDR-AB pneumonia.

Keywords: Acinetobacter baumannii; Colistin; Extensively drug-resistant; Outcomes; Pneumonia; Treatment.

PubMed Disclaimer

Comment in

  • Response to: tigecycline and pneumonia.
    Khawcharoenporn T, Apisarnthanarak A. Khawcharoenporn T, et al. Int J Antimicrob Agents. 2014 Aug;44(2):181. doi: 10.1016/j.ijantimicag.2014.05.003. Epub 2014 Jun 10. Int J Antimicrob Agents. 2014. PMID: 25059443 No abstract available.
  • Tigecycline and pneumonia.
    Oğütlü A, Karabay O. Oğütlü A, et al. Int J Antimicrob Agents. 2014 Aug;44(2):180-1. doi: 10.1016/j.ijantimicag.2014.05.001. Epub 2014 Jun 10. Int J Antimicrob Agents. 2014. PMID: 25059445 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources